Equities Analysts Set Expectations for argenx Q2 Earnings

argenx SE (NASDAQ:ARGX) – Analysts at Wedbush upped their Q2 2025 earnings per share estimates for argenx in a report released on Friday, December 27th. Wedbush analyst D. Nierengarten now anticipates that the company will post earnings of $2.26 per share for the quarter, up from their prior estimate of $2.23. Wedbush has a “Outperform” rating and a $655.00 price objective on the stock. The consensus estimate for argenx’s current full-year earnings is $2.20 per share. Wedbush also issued estimates for argenx’s Q3 2025 earnings at $2.70 EPS, Q4 2025 earnings at $3.07 EPS and FY2025 earnings at $9.94 EPS.

ARGX has been the subject of several other research reports. Deutsche Bank Aktiengesellschaft cut argenx from a “buy” rating to a “hold” rating in a research note on Friday, October 4th. Truist Financial boosted their target price on argenx from $540.00 to $660.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Evercore ISI raised their price target on argenx from $675.00 to $706.00 and gave the company an “outperform” rating in a report on Thursday, November 21st. Oppenheimer reaffirmed an “outperform” rating and set a $675.00 price objective (up previously from $646.00) on shares of argenx in a report on Thursday, November 21st. Finally, JPMorgan Chase & Co. raised their target price on argenx from $640.00 to $670.00 and gave the company an “overweight” rating in a report on Monday, November 4th. Three equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $639.78.

argenx Trading Down 1.0 %

Shares of NASDAQ ARGX opened at $619.96 on Monday. argenx has a 12-month low of $349.86 and a 12-month high of $644.97. The business’s fifty day simple moving average is $599.42 and its 200-day simple moving average is $533.19. The stock has a market cap of $37.43 billion, a P/E ratio of -704.50 and a beta of 0.59.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.39 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.10 by $1.29. argenx had a negative return on equity of 1.45% and a negative net margin of 2.11%. The firm had revenue of $588.88 million for the quarter, compared to the consensus estimate of $543.29 million. During the same quarter in the previous year, the business earned ($1.25) EPS.

Institutional Trading of argenx

Institutional investors have recently added to or reduced their stakes in the business. Point72 Hong Kong Ltd purchased a new stake in shares of argenx in the second quarter worth about $76,000. Cromwell Holdings LLC boosted its holdings in argenx by 73.3% in the 3rd quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock worth $85,000 after acquiring an additional 66 shares during the period. GAMMA Investing LLC grew its position in argenx by 47.5% in the third quarter. GAMMA Investing LLC now owns 174 shares of the company’s stock valued at $94,000 after acquiring an additional 56 shares in the last quarter. Blue Trust Inc. raised its stake in shares of argenx by 413.9% during the third quarter. Blue Trust Inc. now owns 370 shares of the company’s stock valued at $201,000 after purchasing an additional 298 shares during the period. Finally, Gallacher Capital Management LLC acquired a new position in shares of argenx during the second quarter worth $202,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.